

Curriculum Vitae

Personal information

First name(s) / Surname(s) **Simone Scagnoli, MD, PhD**

Work and Research experience

Dates **16/03/2023 → ongoing**

Occupation Researcher (RTDA)

Name and address of employer "Sapienza" University of Rome – Dipartimento di Scienze Radiologiche, Oncologiche e Anatomopatologiche, viale del policlinico 155, Roma, 00161 (Italy)

Dates **22/12/2019 → 30/01/2023**

Occupation or position held Fully founded PhD in PhD programme "Oncologia" curriculum "Metodologia di ricerca sperimentale e clinica in oncologia"

Main activities and responsibilities Oncology referral for several translational and clinical research programs

Name and address of employer "Sapienza" University of Rome – Dipartimento di Scienze Medico-Chirurgiche e Medicina Traslazionale Ospedale Sant'Andrea, Via di Grottarossa, 1035/1039, 00189 Roma (Italy)

Dates **2019 → 2022**

Occupation or position held Lecturer - II Level Master in Immuno-Oncologia and II level Master in Senologia

Name and address of employer "Sapienza" University of Rome

Dates **2021 → 2022**

Occupation or position held Reviewer

Main activities and responsibilities Peer Reviewer; Article reviewer

Name and address of employer a. Frontiers (Frontiers Media S.A)
b. Cancers (MDPI; Basel, Switzerland)
c. Journal of Translational Medicine (Springer Nature)

Dates **10/12/2014 → 20/12/2019**

Occupation or position held Fellow as Medical Doctor in training for Medical Oncology at Medical Oncology school "Sapienza" University of Rome

Main activities and responsibilities Medical Doctor involved in management of patients with solid tumors

Name and address of employer "Sapienza" University of Rome – AOU Policlinico Umberto I - UOC Oncologia B Viale Regina Elena 324, 00161 Rome (Italy)

Dates **2014 → 2022**

Occupation or position held Active participation to multidisciplinary unit "Breast Unit" of Policlinico Umberto I, "Sapienza" University of Rome

Main activities and responsibilities Directly involved in multidisciplinary management of patients with breast cancer

Name and address of employer "Sapienza" University of Rome – AOU Policlinico Umberto I – UOC Oncologia
Viale Regina Elena 324, 00161 Rome (Italy)

Dates **2021 → 2022**

Occupation or position held Coordination activities and participation to national Molecular Tumor Board (MTB) in Rome Trial

Main activities and responsibilities Management of genomics reports and clinical case discussion

Name and address of employer Fondazione Medicina Personalizzata (FMP) and "Sapienza" University of Rome

Dates **2021 → 2022**

Occupation or position held Active participation to multidisciplinary unit "Skin Unit" of Policlinico Umberto I, "Sapienza" University of Rome

Main activities and responsibilities Directly involved in multidisciplinary management of patients with melanoma or other skin cancers

Name and address of employer "Sapienza" University of Rome - Policlinico Umberto I - U.O.C. Oncologia
Viale Regina Elena 324, 00161 Rome (Italy)

Dates **13/03/2013 - 10/10/2014**

Occupation or position held Medical fellow

Main activities and responsibilities Observation of clinical activity and management of patients affected by solid tumours

Name and address of employer "Sapienza" University of Rome – AOU Policlinico Umberto I – UOC Oncologia B
Viale Regina Elena 324, 00161 Rome (Italy)

Dates **02/01/2012 - 30/07/2013**

Occupation or position held Medical student

Main activities and responsibilities Observation of clinical activity in Oncological Unit

Name and address of employer Sapienza University of Rome – AOU Policlinico Umberto I
Viale Regina Elena 324, 00161 Rome (Italy)

Education and training

Dates **20/12/2020**

Title of qualification awarded Specialist in "Medical Oncology"
Score: 70 e lode/70
Thesis: "Profilo immunologico tissutale del carcinoma della mammella triplo negativo nel setting neoadiuvante"

Name and type of organisation providing education and training Sapienza University of Rome
Piazzale Aldo Moro 5, 00161 Rome (Italy)

Dates **01/11/2013 → 31/01/2014**

Title of qualification awarded National Board Exame
Registration to the Provincial Order of Physician of Rome on 13/03/2014 (member n°60777)

Name and type of organisation providing education and training Sapienza University of Rome
Piazzale Aldo Moro 5, 00161 Rome (Italy)

Dates **October 2007 → 30/07/2013**

Title of qualification awarded Degree
Score: 110/110 cum laude
Thesis: "Il trattamento delle metastasi epatiche nel carcinoma colo-rettale: analisi di efficacia e sicurezza della radio-embolizzazione epatica selettiva (SIRT) nell'era delle terapie target"

Name and type of organisation providing education and training Sapienza University of Rome
Piazzale Aldo Moro 5, 00161 Rome (Italy)

Level in national or international classification ISCED 5

Dates **September 2002 → July 2007**

Title of qualification awarded High school degree (95/100)

Name and type of organisation providing education and training Liceo scientifico "Vito Volterra"
Ciampino RM (Italy)

Level in national or international classification ISCED 4

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment
European level ()*

Understanding

Speaking

Writing

Listening Reading Spoken interaction Spoken production

English C1 Independent user C1 Independent user C1 Independent user C1 Independent user C1 Independent user

(*) [Common European Framework of Reference \(CEF\) level](#)

Social skills and competences - Team spirit
- Determination
- Excellent oral and written communication skills

Organisational skills and competences - Good experience in project or team management
- Leadership
- Sense of organization

Technical skills and competences - Formulate a diagnosis
- Propose a diagnostic and therapeutic plan
- Management of patients affected by solid tumour
- Management of early and advanced breast cancer
- Management of principal medical emergencies

Computer skills and competences - Good experience of Microsoft programs (ECDL)
- Good experience with the main statistical programs (SPSS)

Additional Information

Since January 2015 to nowadays I have been attending several clinical trials according to G.C.P as Sub-Investigator:

- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) (NCT04591431);
- Evaluation of a tissue immune profile (TIP) in patients affected by metastatic TNBC treated with upfront atezolizumab plus nab-paclitaxel;
- GIM21 (LiqERBcept): Liquid Biopsy: intercepting mutational trajectories of HER2 breast cancer in patients under T-DM1 treatment;
- JAVELIN BRCA/ATM a phase 2 study to evaluate safety and anti-tumor activity of avelumab in combination with talazoparib in patients with brca or atm mutant tumors (B9991032)
- COMPLEMENT-1: an open-label multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with no prior hormonal therapy for advanced disease (CLEE011A2402)
- IMPASSION 131: a phase III, multicentre, randomized, double blind, placebo-controlled study of atezolizumab in combination with paclitaxel for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (MO30196)
- LUCY: a phase IIIb, single arm, open label multicentre study of Olaparib monotherapy in the treatment of HER2-ve Metastatic Breast Cancer Patients with germline BRCA1/2 mutations (D0816C00018)
- Italian Expanded Access Programme of Nivolumab in advanced/metastatic squamous and non-squamous lung cancer
- Italian Expanded Access Programme of Nivolumab in advanced/metastatic RCC
- VALENTINO: first-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single agent Panitumumab as maintenance therapy in patients with RAS wild-type, metastatic colorectal cancer: the Valentino study (2015-000333-71)
- TRIBE2: a phase III study, first-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in first and second-line treatment of unresectable metastatic colorectal cancer (2014-004436-19)
- PRESIDE: a randomized, double blind, placebo-controlled, phase IIIb study of the efficacy and safety of continuing Enzalutamide in chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients treated with Docetaxel plus Prednisone who have progressed on Enzalutamide alone (9785-MA-1001)

PUBLICATIONS

Articles:

1. Tissue immune profile: a tool to predict response to neoadjuvant therapy in triple negative breast cancer / Cerbelli, B.; Scagnoli, S.; Mezi, S.; De Luca, A.; Pisegna, S.; Amabile, M. I.; Roberto, M.; Fortunato, L.; Costarelli, L.; Pernazza, A.; Strigari, L.; Rocca, C. D.; Marchetti, P.; D'amati, G.; Botticelli, A.. - In: **CANCERS**. - ISSN 2072-6694. - 12:9(2020), pp. 1-12. as coprimary author IF: 6.126

2. The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy / Botticelli, A.; Cirillo, A.; Scagnoli, S.*; Cerbelli, B.; Strigari, L.; Cortellini, A.; Pizzuti, L.; Vici, P.; De Galitiis, F.; Di Pietro, F. R.; Cerbelli, E.; Ghidini, M.; D'amati, G.; Rocca, C. D.; Mezi, S.; Gelibter, A.; Giusti, R.; Cortesi, E.; Ascierto, P. A.; Nuti, M.; Marchetti, P.. - In: VACCINES. - ISSN 2076-393X. - 8:2(2020), p. 203. as Corresponding author IF: 4.086

3. 5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine / Botticelli, A.; Scagnoli, S.; Roberto, M.; Lionetto, L.; Cerbelli, B.; Simmaco, M.; Marchetti, P.. - In: JOURNAL OF ONCOLOGY PHARMACY PRACTICE. - ISSN 1078-1552. - (2020). As second and corresponding author IF: 1.850

4. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study / Nigro, O.; Pinotti, G.; De Galitiis, F.; Di Pietro, F. R.; Giusti, R.; Filetti, M.; Bersanelli, M.; Lazzarin, A.; Bordi, P.; Catino, A.; Pizzutilo, P.; Galetta, D.; Marchetti, P.; Botticelli, A.; Scagnoli, S.; Russano, M.; Santini, D.; Torniai, M.; Berardi, R.; Ricciuti, B.; De Giglio, A.; Chiari, R.; Russo, A.; Adamo, V.; Tudini, M.; Silva, R. R.; Bolzacchini, E.; Giordano, M.; Di Marino, P.; De Tursi, M.; Rijavec, E.; Ghidini, M.; Vallini, I.; Stucci, L. S.; Tucci, M.; Pala, L.; Conforti, F.; Queirolo, P.; Tanda, E.; Spagnolo, F.; Cecchi, F.; Bracarda, S.; Macrini, S.; Santoni, M.; Battelli, N.; Fagnoli, M. C.; Porzio, G.; Tuzi, A.; Suter, M. B.; Ficorella, C.; Cortellini, A.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 134(2020), pp. 19-28. IF: 7.275

5. Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer. Potential molecular mechanisms, clinical implications and future perspectives / Roberto, M.; Astone, A.; Botticelli, A.; Carbone, L.; Cassano, A.; D'auria, G.; Fabbri, A.; Fabi, A.; Gamucci, T.; Krasniqi, E.; Minelli, M.; Orlandi, A.; Pantano, F.; Paris, I.; Pizzuti, L.; Portarena, I.; Salesi, N.; Scagnoli, S.; Scavina, P.; Tonini, G.; Vici, P.; Marchetti, P.. - In: CANCERS. - ISSN 2072-6694. - 13:2(2021), pp. 1-20. IF: 6.126

6. Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma / Zizzari, Ilaria Grazia; Napoletano, Chiara; Di Filippo, Alessandra; Botticelli, Andrea; Gelibter, Alain Jonathan; Calabro', Fabio; Rossi, Ernesto; Schinzari, Giovanni; Urbano, Federica; Pomati, Giulia; Scagnoli, Simone; Rughetti, Aurelia; Caponnetto, Salvatore; Marchetti, Paolo; Nuti, Marianna. - In: CANCERS. - ISSN 2072-6694. - 12:9(2020). IF: 6.126

7. Second medical opinion in oncological setting Maruzzo, M., La Verde, N., Russo, A., Marchetti, P., Scagnoli, S., Gonzato, O., Di Maio, M., Zagonel, V., Galvano, A., Lanzetta, G., Perrone, F., Beretta, G., Bordonaro, R., Comandone, A., Cinieri, S., Nicolis, F., Gori, S. (2021) Critical Reviews in Oncology/Hematology, 160, art. no. 103282 IF: 5.833

8. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1 / Botticelli, A.; Mezi, S.; Pomati, G.; Cerbelli, B.; Cerbelli, E.; Roberto, M.; Giusti, R.; Cortellini, A.; Lionetto, L.; Scagnoli, S.; Zizzari, I. G.; Nuti, M.; Simmaco, M.; Marchetti, P.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 11:Jul 7(2020), pp. 1-13. IF: 5.085

9. Soluble Immune checkpoints, gut metabolites and performance status as parameters of response to Nivolumab treatment in NSCLC patients / Zizzari, Ilaria Grazia; Di Filippo, Alessandra; Scirocchi, Fabio; Di Pietro, Francesca Romana; Rahimi Koshkaki, Hassan; Ugolini, Alessio; Scagnoli, Simone; Vernocchi, Pamela; Del Chierico, Federica; Putignani, Lorenza; Rughetti, Aurelia; Marchetti, Paolo; Nuti, Marianna; Botticelli, Andrea; Napoletano, Chiara. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 10:4(2020). IF: 4.433

10. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Target Oncol. 2018 Mar 27. doi: 10.1007/s11523-018-0562-5. [Epub ahead of print] PMID: 29582224 IF 4.036

11. "Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience" Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airolfi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L,

De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. *J Cell Physiol.* 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. IF: 5.546

12. “Adjuvant chemotherapy in resected colon cancer: When, how and how long?” Gelibter A.J., Caponnetto S., Urbano F., Emiliani A. Scagnoli S., Sirgiovanni G., Napoli V, Cortesi E. *Surgical Oncology Volume 30*, September 2019, Pages 100-107 <https://doi.org/10.1016/j.suronc.2019.06.003> IF: 2.521

13. The role of opioids in cancer response to immunotherapy / Botticelli, Andrea; Cirillo, Alessio; Pomati, Giulia; Cerbelli, Bruna; Scagnoli, Simone; Roberto, Michela; Gelibter, Alain; Mammoni, Giulia; Calandrella, Maria Letizia; Cerbelli, Edoardo; Di Pietro, Francesca Romana; De Galitiis, Federica; Lanzetta, Gaetano; Cortesi, Enrico; Mezi, Silvia; Marchetti, Paolo. - In: *JOURNAL OF TRANSLATIONAL MEDICINE.* - ISSN 1479-5876. - 19:1(2021). IF 4.124

14. Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer / Mezi, S.; Botticelli, A.; Pomati, G.; Cerbelli, B.; Scagnoli, S.; Amirhassankhani, S.; D'amati, G.; Marchetti, P.. - In: *CANCERS.* - ISSN 2072-6694. - 13:5(2021). IF: 6.126

15. “Burned-Out Testicular Cancer: Really a Different History?” Mosillo C, Scagnoli S, Pomati G, Caponnetto S, Mancini ML, Bezzi M, Cortesi E, Gelibter A. *Case Rep Oncol.* 2017 Sep 20;10(3):846-850. doi: 10.1159/000480493. eCollection 2017 Sep-Dec. PMID: 29071000 IF: 1.501

16. Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report. Magri V, Scagnoli S, Piesco G, Pomati G Abtpn [Internet]. 31Oct.2018 [cited 16Jul.2019];4(1):185-90.Available from: <https://journals.aboutscience.eu/index.php/aboutopen/article/view/131>

17. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET). Vernieri C, Nichetti F, Lalli L, Moschetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. *Clin Cancer Res.* 2021 Mar 30;clincanres.4928.2020. doi: 10.1158/1078-0432.CCR-20-4928. PMID: 33785482 IF: 10.107

18. Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response Scirocchi, Fabio;Scagnoli, Simone; Botticelli, Andrea A.;Di Filippo, Alessandra;Napoletano, Chiara;Zizzari, Ilaria Grazia;Strigari, Lidia;Tomao, Silverio;Cortesi, Enrico;Rughetti, Aurelia;Marchetti, Paolo;Nuti, Marianna *eBioMedicine Open Access Volume 79 May 2022 Article number 104010 ISSN 23523964 DOI 10.1016/j.ebiom.2022.104010* IF 11.205

19. The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature Botticelli, Andrea ;Fabbri, Agnese;Roberto, Michela; Alesini, Daniele;Cirillo, Alessio; D'Auria, Giuliana;Krasniqi, Eriseld;Marrucci, Eleonora;Muratore, Margherita;Pantano, Francesco;Pizzuti, Laura;Portarena, Ilaria *Frontiers in Oncology Open Access Volume 12 9 February 2022 Article number 797157 ISSN 2234943X DOI 10.3389/fonc.2022.797157*; IF: 5.738

20. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting Pizzuti, Laura; Krasniqi, Eriseld; Sperduti, Isabella; Barba, Maddalena; Gamucci, Teresa; Mauri, Maria; Veltri, Enzo Maria; Meattini, Icro; Berardi, Rossana; Di Lisa, Francesca Sofia; Natoli, Clara; Pistelli, Mirco, Simone Scagnoli et al *Therapeutic Advances in Medical Oncology Open Access Volume 13 November 2021 ISSN 17588340 DOI 10.1177/17588359211059873*; IF 5.485

21. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis Botticelli, Andrea;Cirillo, Alessio;Strigari, Lidia;Valentini, Filippo;Cerbelli, Bruna;Scagnoli, Simone;Cerbelli,

22. The role of soluble lag3 and soluble immune checkpoints profile in advanced head and neck cancer: A pilot study Botticelli, Andrea, Zizzari, Ilaria Grazia; Scagnoli, Simone; Pomati, Giulia; Strigari, Lidia; Cirillo, Alessio; Cerbelli, Bruna; Di Filippo, Alessandra; Napoletano, Chiara; Scirocchi, Fabio; Rughetti, Aurelia; Nuti, Marianna; Journal of Personalized Medicine Open Access Volume 11, Issue 7 July 2021 Article number 651 ISSN 20754426 DOI 10.3390/jpm11070651 IF 3.508

23. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy Andrea Botticelli, Giulia Pomati, Alessio Cirillo, Simone Scagnoli, Simona Pisegna, Antonella Chiavassa, Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora, Bruna Cerbelli, Alessandra Di Filippo, Sasan Amirhassankhani, Alessandro Scala, Ilaria Grazia Zizzari, Enrico Cortesi, Silverio Tomao, Marianna Nuti, Silvia Mezi, Paolo Marchetti Front. Immunol., 03 November 2022 <https://doi.org/10.3389/fimmu.2022.974087> IF 8.786

Abstracts:

- 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial A Botticelli, S Scagnoli, PF Conte, C Cremolini, PA Ascierto, F Cappuzzo, M Aglietta, F Mazzuca, E Capoluongo, G Blandino, U Malapelle, M Nuti, G D'Amati, B Cerbelli, G Pruneri, M Biffoni, G Giannini, F Cognetti, G Curigliano, P Marchetti; Annals of Oncology, 2022 VOLUME 33, SUPPLEMENT 7, S1304-S1305, SEPTEMBER 01, 2022 DOI: <https://doi.org/10.1016/j.annonc.2022.07.1745>

- Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial. Andrea Botticelli, Simone Scagnoli, Pierfranco Conte, Chiara Cremolini, Paolo Antonio Ascierto, Federico Cappuzzo, Massimo Aglietta, Federica Mazzuca, Ettore Capoluongo, Giovanni Blandino, Umberto Malapelle, Marianna Nuti, Giulia D'Amati, Bruna Cerbelli, Giancarlo Pruneri, Mauro Biffoni, Giuseppe Giannini, Francesco Cognetti, Giuseppe Curigliano, Paolo Marchetti Journal of Clinical Oncology 2022 vol 40 DOI: 10.1200/JCO.2022.40.16_suppl.3087 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 3087-3087.

- 267P AB-ITALY: The impact of drug-drug interaction on abemaciclib treatment in Italian real world experience A Botticelli, S Scagnoli, S Pisegna, A Toss, A Fabi, C Criscitiello, G D'Auria, MA Fabbri, A Orlandi, V Barberi, R Caputo, P Vici, M Palleschi, D Santini, G Tomasello, E Ricevuto, M Simmaco, R Preissner, E Cortesi, P Marchetti Annals of Oncology 2022 vol 33 VOLUME 33, SUPPLEMENT 7, S659-S660, SEPTEMBER 01, 2022 DOI: <https://doi.org/10.1016/j.annonc.2022.07.306>

- 337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study F. Nichetti, A. Marra, C.A. Giorgi, G. Randon, S. Scagnoli, C. De Angelis, C. Molinelli, E. Ferraro D. Trapani, A. Milani, E. Agostinetti, O. Bernocchi, G. Catania, C.G. Rea, D. Basile, L. Gerratana M. Cinausero, C. Vernieri; Annals of Oncology 31, SUPPLEMENT 4, S382, SEPTEMBER 01, 2020 DOI: <https://doi.org/10.1016/j.annonc.2020.08.439>

- Abstract P5-11-18: Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study Alessandra Fabi; Michelangelo Russillo; Mariangela Ciccicarese; Simone Scagnoli; Francesco Schettini; Giuseppe Buono; Vito Lo Russo; Grazia Arpino; Rosalba Rossella; Giuseppina Sarobba; Marianna Giampaglia; Patrizia Pellegrini; Simonetta Stani; Michela Palleschi; Vincenzo Adamo; Francesca Morelli; Maria Agnese Fabbri; Cecilia Nistico; Gianluigi Ferretti; Giovanna Catania; Simona Pisegna; Diana Giannarelli; Francesco Cognetti Cancer Res (2020) 80 (4_Supplement): P5-11-18. <https://doi.org/10.1158/1538-7445.SABCS19-P5-11-18>

- Tissue immune profile can predict response to neoadjuvant therapy in tnbc abstract and poster AIOM 2020 Scagnoli S. Cerbelli Bruna, Mezi Silvia, Pisegna Simona, De Luca Alessandro, Amabile Marida, Roberto Michela, Strigari Lidia, Fortunato Lucio, Costarelli Leopoldo, Della Rocca Carlo, Marchetti Paolo, D'Amati Giulia, Botticelli Andrea

- Abstract P4-13-07: *SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2*

negative (-) metastatic breast cancer (MBC)

A Fabi, D Giannarelli, A Botticelli, **S Scagnoli**, A Pellegrino, A Fabbri, D Corsi, V Magri, L Pizzuti, I Paris, V Bruni, R Pace, G Lanzetta, S Stani, L Moscetti, P Marchetti, G Piesco, F Cognetti and V Rossi DOI: 10.1158/1538-7445.SABCS18-P4-13-07 Published February 2019

- *P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)* Francesco Grossi, Lucio Crinò, Annamaria Catino, Stefania Canova, Angelo Delmonte, Andrea Ardizzoni, Marina Garassino, **Simone Scagnoli**, Federico Cappuzzo, Daniele Turci, Silvia Quadrini, Paola Antonelli, Paolo Marchetti, Armando Santoro, Sabrina Giusti, Francesco Di Costanzo, Francesca Rastelli, Paolo Sandri, Lorenzo Livi, Filippo De Marinis *Journal of Thoracic Oncology*, Volume 12, Issue 1, S1337 - S1338 DOI: <https://doi.org/10.1016/j.jtho.2016.11.1892>

- *Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.* Lucio Crino, Paolo Bidoli, Angelo Delmonte, Francesco Grossi, Filippo De Marinis, Francesca Sperandi, Fabiana Vitiello, Milena Vitali, Hector J. Soto Parra, **Simone Scagnoli**, Gabriele Minuti, Luana Calabrò, Marcello Tiseo, Daniele Turci, Silvia Quadrini, Paola Antonelli, Anna Manzo, Irene Prediletto, Diana Giannarelli, and Domenico Galetta *Journal of Clinical Oncology* 2016 34:15_suppl, 3067-3067

- *Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population* L. Crinò P. Bidoli A. Delmonte, F. Grossi, F. de Marinis, F. Sperandi, F. Piantedosi M. Vitali, H. Soto Parra, S. Scagnoli, G. Minuti, L. Calabrò, M. Tiseo, D. Turci, S. Quadrini, P. Antonelli A. Manzo, I. Prediletto, D. Giannarelli, D. Galetta *Annals of Oncology* VOLUME 27, SUPPLEMENT 4, IV3, SEPTEMBER 01, 2016 DOI: <https://doi.org/10.1093/annonc/mdw332.01>

- *Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.* Orazio Caffo, Emilio Bria, Ugo De Giorgi, Marcello Tucci, Elisa Biasco, Lucia Fratino, Gaetano Facchini, Roberto Iacovelli, Giovanni Lo Re, **Simone Scagnoli**, Franco Morelli, Alessandro D'Angelo, Francesco Verderame, Enrico Campadelli, Riccardo Ricotta, Martina Napolitano, Donata Sartori, Nicolo Borsellino, Isabella Sperduti, and Marco Maruzzo *Journal of Clinical Oncology* 2017 35:15_suppl, e16521-e16521

- *P1. 15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience* M Bassanelli, D Giannarelli, B Ricciuti, V Magri, FL Cecere, M Roberto, S Giacinti, V Barucca, R Cassese, A De Giglio, S Scagnoli, M Milella, M Santarelli, C Bengala, EM Ruggeri, P Marchetti, F Cognetti, A Gelibter, E Cortesi, R Chiari, A Ceribelli *Journal of Thoracic Oncology* VOLUME 13, ISSUE 10, SUPPLEMENT, S611, OCTOBER 01, 2018

- *Real world data from the Italian expanded access program (EAP): updated safety and efficacy results of nivolumab for metastatic renal cell carcinoma (mRCC)* De Giorgi U, Carteni G.2, Basso U, Galli L, **Scagnoli S**, Caserta C, Pignata S, Guida A, Bearz A, Buti S, Lo Re G, Berruti A, Hamzaj A, Cognetti F., Rastelli F, Damiani A., Porta C., Losanno T., Turci D, Procopio G accepted for AXIX Congresso Nazionale AIOM

- *Cardiovascular risk in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. a meta-analysis* Daniele Alesini, Roberto Iacovelli, Michela Palleschi, Alessia Pochesci, Daniela Modica, Ilaria Attili, Gabriele Piesco, **Simone Scagnoli**, Valentina Orlando, Enrico Cortesi *Archivio Italiano Urologia e Andrologia* Vol. 85; n. 2, Supplement 1, June 2013

- *Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety* E. Cortesi, G. Masi, M. Mancini, S. Caponnetto, F. Urbano, C. Mosillo, **S. Scagnoli**, E. Notarianni, G. Pelle, C. Vivaldi, A. Falcone, R. Cianni; *P-158 Annals of Oncology*, Volume 27, Issue suppl_2, 1 June 2016, Pages ii47, <https://doi.org/10.1093/annonc/mdw199.152>

- *A36 Prolactin as a possible predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)*, S. Caponnetto, M.L. Mancini, **S. Scagnoli**, G. Barchiesi, C. Mosillo, G.M. Iannantuono, S. Verkhovskaia, V. Magri, G. Piesco, G. Pomati, D. Pellegrino, F. Urbano, S. Zancla, C. Manai, E. Cortesi; *Annals of Oncology*, Volume 27, Issue suppl_4, 21 September 2016, Pages iv14, <https://doi.org/10.1093/annonc/mdw332.36>

- *Safety and efficacy profile of ramucirumab alone or combined with paclitaxel in metastatic gastric cancer (MGC): A real-life overview of compassionate-use named patients (pts) (RAMoss study)*, M. Di

Bartolomeo, M. Niger, M.M. Laterza, C. Vivaldi, E. Giommoni, A. Zaniboni, S. Bozzarelli, G. Tomasello, T. Sava, M. Spada, A. Bittoni, S. Galdy, A. Spallanzani, F. Bassan, **S. Scagnoli**, F. Morano, R. Berenato, M. Caporale, P. Filippo, F. De Vita; *Annals of Oncology*, Volume 27, Issue suppl_6, 1 October 2016, 636P, <https://doi.org/10.1093/annonc/mdw371.28>

- Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence S Caponnetto, A Gelibter, C Mosillo, V Magri, **S Scagnoli**, G Pomati, G Piesco, S Verkhovskaya, S Pisegna, G Sirgiovanni, V Napoli, D Buscicchio, G M Iannantuono, D Marinelli, G Mammone, S Pannunzio, E Nicolò, A Stefani, V Astorino, M Mancini, E Cortesi. *Annals of Oncology*, Volume 28, Issue suppl_6, 1 October 2017, mdx425.026, <https://doi.org/10.1093/annonc/mdx425.026>

- Safety and toxicity in elderly patients in treatment for metastatic colon cancer. M. Mancini, C. Mosillo, S. Caponnetto, F. Urbano, C. Manai, D. Modica, **S. Scagnoli**, E. Cortesi; *E50 Annals of Oncology* Volume 26, Issue suppl_6, 1 October 2015, Pages vi51, <https://doi.org/10.1093/annonc/mdv340.50>

- Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC). Maria Bassanelli, Diana Giannarelli, Alain Gelibter, Fabiana Letizia Cecere, Rita Chiari, Silvana Giacinti, **Simone Scagnoli**, Michele Milella, Biagio Ricciuti, Michela Roberto, Valentina Magri, Virginia Ferraresi, Marta Brambilla, Mario Santarelli, Paolo Marchetti, Enrico Cortesi, and Anna Ceribelli *Journal of Clinical Oncology* 2018 36:5_suppl, 177-177

- Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.

Maria Bassanelli, Diana Giannarelli, Biagio Ricciuti, Valentina Magri, Fabiana Letizia Cecere, Michela Roberto, Silvana Giacinti, Viola Barucca, Raffaele Cassese, Andrea De Giglio, **Simone Scagnoli**, Michele Milella, Mario Santarelli, Carmelo Bengala, Enzo Maria Ruggeri, Paolo Marchetti, Francesco Cognetti, Alain Gelibter, Rita Chiari, and Anna Ceribelli *Journal of Clinical Oncology* 2018 36:15_suppl, e15158-e15158

INVITED TALKS:

- YO-IO Oncologist in Immunoncology 3.0 “nuove prospettive dell’immunoterapia nel carcinoma della mammella” 11/11/2022
- HER 2 WIN, Webinar, 07.10.2022
- LA TARGET THERAPY NEL TRATTAMENTO DEL MELANOMA Roma, 24/05/22 - Istituto S. E. De Vialar, Via Paolo III, 16
- BREAST TALENT 3.0, Webinar, 18.03.2022
- Breast Cancer Challenge the experts – Napoli – 21.02.2022
- “Corso teorico e pratico sulla medicina di precision ed oncologia mutazionale” FAD webinar 25/10/21-22/11/21 – 20/12/21
- Best of the Year 2021 AIOM Lazio Roma 03/12/2021
- YO-IO: young oncologists in immunoncology, Webinar, 19.11.2021
- Casi difficili in immuno-oncologia 3.0, Webinar, 15.12.2021 “melanoma”
- “Dallo studio clinico al real world: nuove tecnologie e nuovi dati nel carcinoma mammario” 15/09/2021; webinar
- ABC day - ADVANCED BrEAsT CANCER DAY 15 GIUGNO 2021 webinar
- CONVERSATIONS Il trattamento della paziente con carcinoma mammario metastatico HER2-/HR+: il ruolo di abemaciclib nella pratica clinica italiana 7 maggio 2021
- Aggiornamenti in oncologia. il trattamento dei tumori limali della mammella: stato dell’arte e prospettive future; webinar FAD asincrona ECM
- “YO Breast – Young Oncologists in Breast Cancer” Board Meeting 24/11/2020
- “Young Care – Gruppo di lavoro sulla medicina di precisione nel tumore della mammella metastatico” Board Meeting 20/11/2020
- Casi Difficili in Immuno-Oncologia 2.0. relazione: Paziente affetto da neoplasia della vescica 15/12/2020
- YO-IO: Young Oncologists in immunoncology relazione: Open issue: the immunological effect of drugs: a new challenge for the second line? 18/11/2020
- Brest Talent. relazione: Presentazione del caso clinico 2 (endocrinosensibile e malattia aggressiva) 25/09/2020
- Casi difficili in immune-oncologia. Relazione: Paziente affetto da melanoma metastatico BRAF mutato, le sequenze 9/12/2019
- “Genetic testing in breast cancer patients: are we in the new era?” Congresso regionale AIOM “From

Texas to Rome – the day after San Antonio” – Roma 17/02/2020

- “L’immunoterapia nei tumori del polmone oncogene-addicted” Congresso “Aggiornamenti di oncologia: i tumori del polmone oncogene addicted” per Fondazione Fatebenefratelli – Roma 12/12/2019
- “Caso clinico: Paziente affetto da neoplasia del polmone in trattamento di 1L con immunoterapia in risposta clinica” - Torre di Babele: il team di immuno oncologia – “sessione beneficio clinico vs risposta radiologica” – Roma 15/11/2019
- “Approccio al paziente con NSCLC ALK+ in progressione dopo trattamento di I linea” Congresso nazionale AIOM Giovani – Sessione educativa “carcinoma polmonare” – Perugia 06/07/2018
- “Targets and microenvironment: what do we know?” “How to better Know the “soul” of Breast Cancer” Post San Antonio Breast Cancer Symposium 2018 AIOM – Roma 28/01/2019
- “Effetti della terapia di deprivazione ormonale nei pz con ca prostatico e razionale di utilizzo del Denosumab nella prevenzione degli eventi scheletrici” Network onco-bone specialist – Roma 15/06/2019

Scientific Board:

- Dallo studio clinico al Real World : nuove tecnologie e nuovi dati nel carcinoma mammario 2.0 16/11/2022; corso ECM
- HER 2 WIN, Webinar, 07.10.2022; corso ECM
- Le Olimpiadi dell’Oncologia Roma, 20 settembre 2022 – corso ECM
- YO-IO 2.0 19/11/21 Webinar – corso ECM
- PRECEPTORSHIP immunoterapia testa-collo e melanoma 30 settembre - 1 ottobre 2021 Roma
- Breast Talent 2.0 18/03/2021 – corso ECM
- L’uomo è ciò che mangia....e ciò che ospita: alimentazione e microbioma 23/04/2021 corso ECM
- YO-IO: Young Oncologists in immunoncology 18/11/2020 – Corso ECM
- Le nuove frontiere dei tumori testa collo 7/10/2020 – Corso ECM
- Breast Talent 25/09/2020 - Corso ECM
- “YO Breast – Young Oncologists in Breast Cancer” Board Meeting 24/11/2020
- “Young Care – Gruppo di lavoro sulla medicina di precisione nel tumore della mammella metastatico” Board Meeting 20/11/2020
- Workshop: “i test genomici nel carcinoma mammario adiuvante verso il superamento delle disparità regionali” Oratorio S. Caterina - Via Monserrato, 111 Roma - 28 febbraio 2020 - Corso ECM

Other:

- ESMO ADVANCED COURSE ON BIOMARKERS FOR PRECISION MEDICINE 28-29 november 2019;
- Breast Cancer Accademy 2021/2022;
- Regular participation to several International Congresses. In 2022 participation to: ESMO congress 2022 Paris, ASCO congress 2022 (online); ESMO breast congress 2022 (online); AIOM 2022 national congress, Rome

Awards:

- Concorso scientifico per casi clinici “SPECIAL CA.RE. 2017” Roma, 03/02/2017

I authorize the use of my personal data according to Italian Law D.L. 196/2003.

Rome 20/03/23